Cytodyn earnings date

Cytodyn earnings date DEFAULT
Earnings Whispers is the only provider of real Earnings Whisper ® numbers - expectations provided by professional analysts for professional fund managers and traders.  Earnings Whisper numbers have been more reliable than consensus estimates more than 70% of the time for almost 20 years.  For this reason, more people rely on Earnings Whisper numbers than any other alternative to consensus estimates and stocks respond more consistently when they differ from the Earnings Whisper than from consensus estimates since our research reflects the expectations of the large institutional investors.
Past performance is not indicative of future results.
Earnings Whispers is the most trusted source for real earnings expectations - relied on by more people than any other earnings-dedicated website.  The Wall Street Journal says EarningsWhispers is the only provider of real whisper numbers from securities analysts.  A Bloomberg News study found EarningsWhispers to be the most accurate source fo earnings expectations.  Academic studies show trading on EarningsWhispers data significantly outperforms the overall market.  Barron's says EarningsWhispers is their favorite source for earnings information.  Michael Lewis, bestselling author of Flash Boys, Liar's Poker, The Big Short, & The Blindside said EarningsWhispers is more reliable than the most highly paid analyst on Wall Street.
Copyright © 1998 - 2021 EarningsWhispers - the professionals' earnings expectation. All rights reserved.
Sours: https://www.earningswhispers.com/stocks/cydy

CYTODYN INC.

Upcoming events on CYTODYN INC.
10/28/21 Annual General Meeting - Proxy Fight for Board Control
11/30/21 | 05:55pm World Antiviral Congress
Past events on CYTODYN INC.
10/13/21 | 01:00pm Emerging Growth Conference
09/29/21 | 02:00pm Emerging Growth Conference
09/15/21 | 03:30pm Emerging Growth Conference
09/08/21 | 04:00pm Business Update Call
07/22/21 | 04:00pm Business Update Call
06/21/21 | 04:00pm Investor Meeting
05/18/21 | 04:00pm Leronlimab FDA Update Call
05/05/21 | 04:00pm Business Update Call
04/28/21 | 05:00pm Triple Negative Breast Cancer Drug Development Digital Summit
04/07/21 | 04:00pm Business Update Call
Past dividends on CYTODYN INC.

- No events available -

Fiscal Period : May2017201820192020
Sales
M $
Released
Forecast
Spread
-27,3
-27,7
1,4%
-45,9
-46,7
1,7%
-55,9
-54,9
-1,7%
-74,6
-68,8
-8,5%
Operating income
(EBITDA)
M $
Released
Forecast
Spread
-25,8
-27,1
5,0%
-50,1
-54,0
7,2%
-59,0
-58,0
-1,8%
-124
-94,8
-31%
Operating profit
(EBIT)
M $
Released
Forecast
Spread
-25,8
-27,1
5,0%
-50,1
-54,0
7,2%
-56,2
-55,1
-1,9%
-124
-94,8
-31%
Pre-Tax Profit
(EBT)
$
Released
Forecast
Spread
-0,19
-0,19
0,00%
-0,29
-0,31
6,5%
-0,21
-0,20
-5,0%
-0,30
-0,22
-36%
Announcement Date07/20/201707/27/201808/14/201908/14/2020
Fiscal Period : May2019 Q42020 Q12020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
Sales
M $
Released
Forecast
Spread


 

0,05
 

0,10
 

1,00
 


 


 


 


 
Operating income
(EBITDA)
M $
Released
Forecast
Spread
-13,8
-12,9
-7,4%
-12,6
-13,5
6,1%
-12,1
-12,4
2,4%
-22,1
-11,8
-88%
-27,8
-22,0
-26%
-25,6
-26,5
3,5%
-24,5
-28,2
13%
-20,7
-24,8
16%
Operating profit
(EBIT)
M $
Released
Forecast
Spread
-14,9
-13,9
-7,5%
-16,2
-14,5
-12%
-14,9
-13,4
-11%
-35,8
-12,8
-181%
-57,6
-28,0
-106%
-30,8
-32,5
5,1%
-35,0
-33,7
-3,9%
-44,0
-30,3
-45%
Pre-Tax Profit
(EBT)
M $
Released
Forecast
Spread
-14,9
-13,9
-7,5%
-16,2
-14,5
-12%
-14,9
-13,4
-11%
-35,8
-12,8
-181%
-57,6
-28,0
-106%
-30,8
-32,5
5,1%
-35,0
-33,7
-3,9%
-44,0
-30,3
-45%
Net income
$
Released
Forecast
Spread
-0,05
-0,04
-25%
-0,04
-0,04
0,00%
-0,04
-0,03
-33%
-0,08
-0,03
-167%
-0,13
-0,05
-160%
-0,06
-0,06
0,00%
-0,06
-0,05
-20%
-0,08
-0,05
-60%
Announcement Date08/14/201910/08/201901/09/202004/09/202008/14/202010/09/202001/08/202104/14/2021
Previous yearPrevious yearNext YearNext Year

Net sales (Year) - Rate of surprise

EPS (Year) - Rate of surprise

Net sales (Quarter) - Rate of surprise

EPS (Quarter) - Rate of surprise

Sours: https://www.marketscreener.com/quote/stock/CYTODYN-INC-120789615/calendar/
  1. Empty spray bottles wholesale
  2. Pharma wisdom
  3. Clone trooper kits
  4. Zotac graphic card warranty

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Source: FactSet

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

Sours: https://www.wsj.com/market-data/quotes/CYDY
CytoDyn, Inc. (OTCQB: CYDY) Emerging Growth Conference 18 October 13 - 2021

Cytodyn Inc Stock , CYDY

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Risk

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Ownerin %
Freefloat89.30
Michael A. Klump2.90
David F. Welch, PhD2.20
Richard G. Pestell1.80
Thomas C Mollick1.55
Jordan G. Naydenov1.23
Samir R. Patel, MD1.13
Jack Chitayat0.71

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Sours: https://markets.businessinsider.com/stocks/cydy-stock

Date cytodyn earnings

Cytodyn Inc
Change company Symbol lookup
Select an option...
CYDY Cytodyn Inc
GFAFX American Funds The Growth Fund of America® Class F-1
SOJD Southern Co
RSIYX Victory RS Investors Fund Class Y
CIEN Ciena Corp
PHIYX PIMCO High Yield Fund Institutional Class
KSTR KraneShares SSE STAR Market 50 Index ETF
MDTC Media Technologies Inc
WSR Whitestone REIT
KGRN KraneShares MSCI China Clean Technology ETF
Go

Company profile

CytoDyn Inc. is a biotechnology company that is focused on developing treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The Company also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The Company is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).

Sours: https://research.tdameritrade.com/grid/public/etfs/profile/profile.asp?symbol=CYDY&fromPage=profile&display=&fromSearch=true
How High Can Clover Health Go? Is CLOV a Good Investment? - Discounted Cash Flow Analysis

Earnings Estimates are an important tool used to evaluate the overall strength and value of a stock. Barchart uses Zack's earnings estimates, generated by their market analysts and used to project profitability. Earnings Estimates are available only for US equities.

>Earnings Surprises

The first table on the Estimates page compares Actual vs. Estimated earnings for the last four quarters. This table is designed to uncover Earnings Surprises — times when a stock's earnings either out-perform or under-perform the analysts' expectations. Typically, when actual earnings out-perform the analysts' estimate, a stock's share price tends to rise; when the actual earnings come in under the analysts' estimate, the stock's share price tends to fall.

>Detailed Earnings Estimates

The second table on the Estimates page shows analyst Earnings Estimates for the next two quarters, along with estimates for the current and next fiscal year. The Average Estimate for each time period is the average for the total number of contributing analysts. The table shows you the number of analysts who submitted estimates, along the with high and low estimate from that group. We also provide the Prior Year's Average Estimate, along with the Growth Rate over the previous year.

Earnings Estimates are one factor to consider, along with the Analyst Ratings for any given stock.

Last 4 Quarters

This widget charts the estimated and reported earnings for the last four quarters.

Key Statistics

Shows key statistics for the symbol:

  • Market Cap: the market value of all outstanding shares (market price * number of outstanding shares)
  • Shares Outstanding: Common shares outstanding as reported by the company on the 10-Q or 10-K.
  • P/E Ratio: Latest closing price divided by the earnings-per-share based on the Latest 12-Month EPS Change (LTM) of earnings. Companies with negative earnings receive an "NE."
  • EPS: The annual earnings per share.
  • Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 36-month historical regression of the return on the stock onto the return on the S&P 500.
  • Earnings: The amount and date of latest Earnings Per Share (EPS) paid out to shareholders.
  • Dividend: Annual dividend, or portion of a company's profit paid to shareholders. Also shows the annual dividend yield percent (latest dividend rate divided by the closing price on that latest dividend date.)
Sours: https://www.barchart.com

Similar news:

CytoDyn Inc. (CYDY)

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.35% per year. These returns cover a period from January 1, 1988 through October 4, 2021. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

Privacy Policy and Terms of Service apply.

Sours: https://www.zacks.com/stock/research/CYDY/earnings-calendar


519 520 521 522 523